Purpose. Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen causing an increasing number of nosocomial infections. Our aim was to evaluate the risk factors and mechanisms associated with trimethoprimsulfamethoxazole (SXT) resistance in S. maltophilia infections in Mexico.
INTRODUCTION
Stenotrophomonas maltophilia is a non-fermenting Gramnegative bacillus that has emerged as an opportunistic drugresistant pathogen that is responsible for an increasing number of nosocomial infections and particularly affects immunocompromised patients, with significant morbidity and mortality [1] [2] [3] . The risk factors for S. maltophilia infections are a severely compromised health status, malignancies, cystic fibrosis, indwelling devices such as intravascular catheters and ventilation tubes, exposure to broadspectrum antimicrobials and prolonged hospitalization [2, 4] . However, the impact of acquiring trimethoprim-sulfamethoxazole (SXT)-resistant S. maltophilia infections has been poorly studied.
S. maltophilia strains tend to have high rates of intrinsic or acquired antimicrobial resistance that reduce our therapeutic options [5] . SXT is a common first-line antimicrobial treatment because resistance rates used to be very low (less than 10 %) [5, 6] . In recent years, however, the SXT resistance rate has been gradually increasing, and it has been reported to be over 38.7 % [7] . Several molecular mechanisms have been shown to contribute to the antimicrobial resistance of S. maltophilia, e.g. the activity of multidrug efflux pumps, such as SmeABC and SmeDEF [8] [9] [10] [11] [12] , and the presence of drug-resistance genes, such as the sul genes [8, 13] .
The aim of this study was to evaluate the risk factors and molecular mechanisms associated with SXT resistance in S. maltophilia infections.
METHODS

Study design
The study was conducted at two tertiary-care Mexican hospitals: the Hospital Universitario Dr Jos e Eleuterio Gonz alez in Nuevo Leon and the Hospital Civil de Guadalajara in Jalisco. Only patients with confirmed S. maltophilia infection were included [14] . Data from the first episode were included if patients had multiple infections with S. maltophilia. Demographic and clinical data were retrieved from patient charts. The Charlson comorbidity index was used as a surrogate measure for comorbidities [15] . Patients whose medical records were unavailable were not included in the statistical analysis. Patients younger than 18 years old were excluded.
Clinical isolates
Clinical isolates of S. maltophilia were collected from February 2007 to August 2015. S. maltophilia isolates were identified using Sensititre panels (TREK Diagnostic Systems, Cleveland, OH, USA) according to the manufacturer's instructions, by PCR amplification of a 134 bp fragment of the 16S rRNA gene [16] and by MALDI-TOF mass spectrometry (Bruker Daltonics, Bremen, Germany). S. maltophilia ATCC 13637 was used as a wild-type control strain. All of the isolates were stored at À70 C until use.
Antimicrobial susceptibility
The minimum inhibitory concentration (MIC) was determined by the broth microdilution method. Panels were obtained from Sensititre (TREK Diagnostic Systems Inc.) and used according to the manufacturer's instructions. The antimicrobial agents for susceptibility testing included amikacin, cefepime, cefotaxime, ceftazidime, chloramphenicol, ciprofloxacin, gentamicin, levofloxacin, meropenem and SXT. The results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) criteria [17] . For antimicrobial agents without specific CLSI criteria for S. maltophilia, criteria that were relevant for non-Enterobacteriaceae were used.
Antimicrobial resistance mechanisms
Sme efflux pump expression Total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Expression of the Sme efflux systems, SmeABC and SmeDEF, was assessed by real-time PCR using previously described specific primers (Table 1) . rDNA was used as the endogenous control gene [9] . Real-time PCR reactions were performed on the Cepheid SmartCycler II real-time PCR system (Cepheid, Sunnyvale, CA, USA). Amplification mixtures were prepared using the SensiFast SYBR No-ROX One-Step kit (Bioline, Taunton, MA, USA) and contained 2Â SensiFast SYBR No-ROX One-Step mix, Reverse GACATGGCCTACCAGGAACAG [9] smeDEF Forward TCGTCCAGGCTGACATTCAA 60 62 [9] Reverse AACGCGGATCGTGATATCG [9] rDNA Forward TGACACTGAGGCACGAAAGC 60 30 [9] Reverse CATCGTTTAGGGCGTGGACTA [9] SXT resistance mechanisms sul1 Forward ATGGTGACGGTGTTCGGCATTCTGA 50 840 [13] Reverse CTAGGCATGATCTAACCCTCGGTCT [13] sul2 Forward GAATAAATCGCTCATCATTTTCGG 50 810 [13] Reverse CGAATTCTTGCGGTTTCTTTCAGC [13] sul3 Forward GAGCAAGATTTTTGGAATCG 51 752 [24] Reverse CATCTGCAGCTAACCTAGGGCTTTGGA [24] ISCR Forward GCGAGTCAATCGCCCACT 50 [13] Reverse CGACTCTGTGATGGATCGAA [13] 1Â reverse transcriptase, 1Â RiboSafe RNase inhibitor, 400 nM of each primer and 10 ng µl À1 of total RNA. After a 5 min retrotranscription step at 45 C and a 2 min activation step at 95 C, the PCR process consisted of 40 cycles of denaturation at 95 C for 15 s, annealing at 60 C for 30 s and extension at 72 C for 30 s. The expression levels of S. maltophilia ATCC 13637 were used to construct the standard curves of smeABC, smeDEF and rDNA, which were used as calibrators to normalize the relative expression levels in clinical isolates. A formula including the Ct values of Sme and the endogenous gene in both the samples and calibrators was used to express n-fold differences in the expression of smeABC or smeDEF genes, in which values of n<1 were considered to indicate overexpression of the Sme efflux system [10] .
SXT resistance mechanisms All of the isolates were screened for the presence of sul1, sul2, and sul3 genes and insertion element common region (ISCR) elements using previously described primers and PCR conditions (Table 1) . Briefly, the reaction mixtures contained 1Â PCR buffer, 2 mM MgCl 2 , 0. 
Statistical analysis
Student's t-test and one-way ANOVA were used to verify significant differences in efflux pump expression between susceptible and resistant isolates. Categorical variables were compared using Fisher's exact test or Chi-squared distribution; continuous variables were analysed using Student's t-test. A multivariate analysis was performed using the logistic regression method to identify independent risk factors associated with SXT-resistant S. maltophilia infections. P<0.05 was considered to be statistically significant. Odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were computed using SPSS statistics software version 20.0 (IMB Corporation, Somers, NY, USA).
RESULTS
Clinical isolates
In total, 196 isolates from 196 patients were collected during the 9-year study period: 169 (86.2 %) isolates were from Nuevo Leon and 27 (13.8 %) were from Jalisco. Most of the isolates were from the respiratory tract (63.3 %, n=124) followed by blood (17.3 %, n=34), wounds (5.1 %, n=10), urine (2.0 %, n=4), abscesses (1.5 %, n=3), pleural fluid (1.5 %, n=3), bile (0.5 %, n=1), cerebrospinal fluid (0.5 %, n=1) and unidentified origin (8.2 %, n=16).
Patient characteristics
One hundred and forty-six patients had a complete medical chart and were included in the clinical analysis ( Table 2) . Antimicrobial susceptibility Table 3 summarizes the susceptibility data. The resistance rates were high for meropenem (93.4 %), gentamicin (55.1 %), ceftazidime (52.3 %), cefotaxime (51.5 %), amikacin (42.3 %) and cefepime (32.1 %). Lower resistance rates were found for ciprofloxacin (26.0 %), SXT (25.0 %), chloramphenicol (14.3 %) and levofloxacin (2.6 %). The comparison of resistant rates per year is shown in Fig. 1 , where the resistance rates to SXT showed a decrease through the years.
Antimicrobial resistance mechanisms
Expression of Sme efflux pumps was analysed in isolates resistant to either quinolones, chloramphenicol, or SXT. Among the 91 selected/included isolates, 68 (74.7 %) overexpressed the SmeABC efflux pump, and 60 (65.9 %) overexpressed the Sme-DEF efflux pump. Overexpression of the SmeABC efflux pump was significantly associated with resistance to gentamicin (P=0.001) and levofloxacin (P=0.041) whereas overexpression of the SmeDEF efflux pump was associated with ceftazidime resistance (P=0.003) ( Table 3) .
SXT resistance was not associated with the presence of either the sul genes (sul1: 4.2 %, n=8; sul2: 0.5 %, n=1; sul3: 0.0 %, n=0) or the ISCR element (0.0 %, n=0). 
Risk factors for SXT-resistant strain infection
DISCUSSION
Clinical and microbiological data from patients infected with S. maltophilia strains from two Mexican tertiary-care hospitals were compared. S. maltophilia mainly affected patients with respiratory infections who had been admitted to the ICU and subjected to multiple invasive procedures. The overall mortality rate of patients with S. maltophilia infection was 45.2 %. Patients in the ICU, or under antibacterial therapy, or with arterial hypertension, type 2 diabetes, acute myocardial infarction, leukaemia, intravascular catheters or ventilation tubes, or experiencing a prolonged stay in hospital, were more likely to die.
According to the data shown above, S. maltophilia mainly affects patients requiring hospitalization in the ICU and with multiple invasive procedures. Attributable mortality could not be clearly defined, however; the infection may have worsened the clinical situation of patients and contributed to the high overall 30day mortality rate detected in this study.
In our patients, a prolonged length of stay (!15 days) was an independent risk factor for infections with SXT-resistant strains. A previous study that included patients with bacteremia by SXT-susceptible and SXT-resistant S. maltophilia showed that mortality rates do not differ between the two study groups, but patients with SXT-resistant isolates experienced prolonged hospitalization after the onset of bacteremia [18] . According to this study and our results, length of stay seems to be the most important risk factor for infection with SXT-resistant strains.
The usage of antibiotics may have favoured the selection of drug-resistant S. maltophilia strains, and a prolonged length of stay may have favoured the dissemination of these drugresistant strains within the hospital.
It is important to highlight the high resistance rate to carbapenems, aminoglycosides and third-generation cephalosporins, because these drugs are used as empirical therapies in most common nosocomial infections. S. maltophilia is intrinsically resistant to several of these groups of antibiotics, including cephalosporins, carbapenems, macrolides and aminoglycosides [5] , and consequently treatment of S. maltophilia infections with these antimicrobial groups is not adequate. The use of these agents may have favoured the colonization or infection with S. maltophilia. Indeed, the use of carbapenems and cephalosporins has been described as a risk factor for the development of S. maltophilia bacteremia [19] . These findings underline the importance of monitoring the incidence and the drug susceptibility of S. maltophilia and underscore the importance of the de-escalation of drugs used in empirical treatment after the causative agent is defined.
SXT is regarded as a first-line drug for the treatment of S. maltophilia infections, because SXT resistance rates used to be less than 10 % in multiple populations [5, 6, 8] . However, SXT resistance rates vary geographically and have been gradually increasing in recent years, reaching values of as high as 32.8 % in our hospitals in 2014 [20] , and reaching 38.7 % in Asian countries [7, 8] . Our follow-up study for 9 years of surveillance data showed a 25 % resistance rate for SXT, with a slight decrease per year. It seems that SXT is no longer the best option to combat S. maltophilia infections in several populations. For our population, levofloxacin and chloramphenicol were the most active agents against S. maltophilia and could be used as appropriate therapeutic options, with special emphasis of levofloxacin against S. maltophilia in respiratory infections [21] .
Several mechanisms for antimicrobial drug resistance have been reported worldwide in isolates of S. maltophilia [8] , including the expression of efflux pumps. Overexpression of the SmeABC pump has been associated with resistance to aminoglycosides [8, 10, 22] and fluoroquinolones [8] [9] [10] . In our study, we confirmed the association of the overexpression of SmeABC with increased resistance to gentamicin and levofloxacin (Table 4) . Furthermore, the overexpression of SmeDEF has been reported to be involved in resistance to quinolones [8, 10, 11, 22] , tetracyclines [8, 22] , macrolides [8] , chloramphenicol [8, 11] and SXT [8, 12, 23] . Interestingly, our results showed that the overexpression of Sme-DEF was associated with increased resistance to ceftazidime ( Table 4 ).
The influence of Sme efflux pumps on the antimicrobial resistance patterns of clinical isolates of S. maltophilia has mainly been reported in Asian countries, such as Taiwan [10, 23] and Korea [9, 22] . Our results represent the first analysis of Sme efflux pump expression and the antimicrobial resistance patterns of clinical isolates of S. maltophilia in Mexico. None of the Sme efflux pumps we analysed were involved in SXT resistance. SXT resistance has been associated with the presence of class 1 integrons and ISCR linked to the sul genes [13] . However, in our strain population, SXT resistance was not associated with the presence of the sul genes, suggesting that other underlying mechanisms are involved.
Our study had several limitations. First, our study had an ambispective design, so selection and observational bias may have occurred. Second, not all isolate or patient data were available. Third, the clonal relationship was not analysed for S. maltophilia isolates. Previously, we reported high genetic diversity among clinical S. maltophilia isolates from Mexico [20] , which suggested independent acquisition rather than cross-transmission. However, the impact of patient-to-patient transmission in the present study cannot be excluded. Finally, other potentially active agents against S. maltophilia, such as ticarcillin/clavulanic acid and minocycline, were not tested in our hospital, and assessments of their clinical effects are unavailable.
In conclusion, this study was the first to evaluate the risk factors associated with SXT-resistant S. maltophilia infections in Mexico. Prolonged length of stay was an independent risk factor for SXT-resistant S. maltophilia infections. Infection with SXT-resistant S. maltophilia did not increase mortality, but it did lead to a prolonged hospital stay. SXT resistance in S. maltophilia was not associated with either SmeABC or SmeDEF pumps, or with sul genes or the ISCR element. As S. maltophilia isolates from our population had a high resistance rate to SXT, it should no longer be the first-line therapy. Instead, levofloxacin could be used as an appropriate therapeutic option against S. maltophilia infections.
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